INTRODUCTION
In recent years, diabetes mellitus has emerged as a global public health concern. Already the most common metabolic disorder, the global prevalence rates of diabetes have been increasing [1] . As of 2012, about 9.3% of the US population (29.1 million people of all ages) were affected by diabetes, which was the seventh leading cause of death in the United States (US) [2] . The American Diabetes Association (ADA) estimated the total costs of diagnosed diabetes to be $245 billion in 2012, which increased from $174 billion in 2007 [3] . Numerous complications are linked to diabetes including heart disease, stroke, hypertension, and kidney disease, which could potentially increase total costs incurred [2] . About 90-95% of all diabetes cases involve type 2 diabetes (T2D); therefore, the clinical and economic burdens incurred by T2D need to be investigated [2] .
Liraglutide is a once-daily glucagon-like peptide-1 (GLP-1) receptor agonist used to improve glycemic control in adults with T2D.
The liraglutide effect and action in diabetes (LEAD) pivotal clinical trials and the 1860 liraglutide dipeptidyl peptidase-4 inhibitor (LIRA-DPP-4) study have analyzed liraglutide against various active comparators across the treatment cascade [4] [5] [6] [7] [8] [9] [10] [11] . These studies have demonstrated that liraglutide improves glycemic control with a low incidence of hypoglycemia, and has the additional benefit of clinically relevant weight loss.
High body mass index (BMI) is an independent risk factor for cardiovascular diseases and all-cause mortality for people with T2D [12, 13] . High BMI, also involved in the pathogenesis of T2D, can complicate the treatment of T2D by altering lipid levels, increasing insulin resistance, and raising blood glucose levels [13] . Several studies have examined changes in body weight, BMI, or body fat over a follow-up period for patients treated with liraglutide, given the effects of excess body weight in T2D patients. Substantial weight reduction [12] [13] [14] [15] [16] [17] [18] or BMI reduction [12, 17, 19] was found in several investigations. However, to date, no study has evaluated the relative clinical effectiveness of liraglutide to achieve glycemic control and weight loss in patients with T2D across baseline BMI levels in real-world clinical practice in the US. The objective of this study is to address this gap and examine liraglutide's effectiveness on glycated hemoglobin A1C (A1C) (a minor component of hemoglobin to which glucose is bound), body weight, cholesterol, and blood pressure across different BMI levels.
METHODS

Data Source
The data for this retrospective cohort study were obtained from the General Electric (GE) 
Compliance with Ethics Guidelines
This study was exempt from ethics approval from an institutional review board and informed consent since it involved assessment of existing data and the subjects could not be identified directly or through identifiers linked to the subjects [45 CFR 46.101(b)].
Sample Selection
Patients were included in the study sample if they had T2D and a prescription order for liraglutide between January 1, 2010, and January 31, 2013. The index date was defined as the date of the first prescription order for liraglutide. T2D was defined using the following criteria: (1) at least one diagnosis for T2D
based on an International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) code for 250.x0 or 250.x2; (2) one or more prescription orders for a noninsulin antidiabetic drug; or (3) two consecutive fasting blood glucose levels of C126 mg/dL [20] .
These analyses focused on outcomes at 6 months after starting liraglutide (6-month post-index).
Patients were excluded if they (1) the baseline and follow-up periods. The baseline value was defined as the value closest to the index date (within 45 days prior to the index date to up to 7 days after). Values for outcomes at 6-month follow-up were defined as the measurements that were obtained on the day closest to 180-day post-index within a ±45-day window. Analysis of variance (ANOVA), for continuous variables, and the Chi-square test, for categorical variables, were used to assess the statistical significance across the BMI categories.
Differences with a P value of less than 0.05 were considered statistically significant. Analyses were performed using SAS software version 9.2 (SAS Institute, Cary, North Carolina, USA).
RESULTS
A total of 3,005 patients with T2D suboptimally controlled at baseline (A1C [7%) initiating liraglutide between January 1, 2010
and January 31, 2013 were identified ( Fig. 1 ). (45 days prior to 7 days after) was low (0.1%). 
Clinical Outcomes
\0.01
Absolute change in weight from baseline, kg [25] . Although these reductions were marginally larger than the overall A1C reduction of 0.94% (AIC reduction ranged from 0.84% and 1.02% depending on BMI categories) found in this current study, the results are comparable given the differences between the tightly controlled setting of a clinical trial and real-world clinical practice.
This same meta-analysis of clinical trials reported that the absolute reduction in body weight from baseline stratified by liraglutide dose ranged from 1.69 kg (1.2 mg) to 2.27 kg (1.8 mg) [25] . Similarly, this study reported an overall absolute body weight reduction of 2.9 kg, ranging from 1.5 kg to 4.0 kg across BMI groups.
The results of this study, by baseline BMI, are consistent with two recently published studies.
No differences were found in A1C reductions across six BMI categories before and after adjustment for baseline factors, such as baseline A1C and ethnicity, using Association Table 2 continued nationwide data from the UK [26] . In addition, in a prospective follow-up study, Fadini et al. [15] found that liraglutide was equally effective in reducing A1C across baseline BMI tertiles measured at 4-month intervals, i.e., the A1C reductions across the BMI tertiles were not statistically significantly different from each other (P = 0.94). Although the authors did not find evidence that A1C reductions were related to baseline BMI, the study did find that absolute and relative reductions in body weight were dependent on baseline BMI, which is consistent with the findings of Fadini et al.
[15] of a statistically significant association between reductions in body weight (kg) at 4-month intervals and baseline BMI tertiles (P\0.01), and with the findings of the UK study conducted by Ryder et al. [26] reporting an association between absolute weight with the meta-analysis of the LEAD pivotal trials conducted by Niswender et al. [13] , namely, those patients with higher baseline BMI lost more relative body weight than patients with lower baseline BMI.
Other outcomes evaluated in this study included severe hypoglycemia, lipids, and blood pressure. The low rate of severe hypoglycemia that the authors found is consistent with liraglutide's glucose-dependent mechanism of action and the results from the Bode et al. [27] meta-analysis. The authors'
findings, that changes in total cholesterol and HDL were independent of baseline BMI, are also, if not indirectly, consistent with the findings that total and HDL cholesterol were not related to changes in body weight reported by Fadini et al. [15] . The overall reductions in SBP and DBP, respectively, were also consistent with those reported by Bode et al. [27] 
Study Limitations
There were several limitations of this study. First, although the authors identified over 3,000 eligible patients with baseline data, relevant laboratory and clinical measures at 6-month follow-up were unavailable for many of them, as expected in a real-world study setting. The impact of this limitation is unclear but the authors do note that the average baseline laboratory and clinical values for the subset of patients with follow-up data were similar to those of the baseline values for the entire sample. Second, it is not possible to determine if patients actually filled or refilled their prescriptions using the GE Centricity EMR database, so the authors could not examine adherence to therapy as an outcome nor were they able to adjust for adherence. Therefore, this study used an intent-to-treat approach. Third, because dose information is often missing from drug records in the GE Centricity EMR database, the authors could not stratify the analyses by liraglutide dose. Fourth, the analyses did not adjust for potential confounding by measured (e.g., age, gender, race) and unmeasured factors (e.g., diet, exercise). Fifth, a post hoc power calculation showed that the statistical power ranged from 40% to 50% for all clinical outcomes except body weight, for which the power was about 90%. The low statistical power may affect the ability to detect changes in clinical outcomes 
CONCLUSION
The authors found that liraglutide was equally effective in reducing A1C across baseline BMI categories suggesting that liraglutide may be effectively used for adult patients with T2D regardless of their BMI level. This study provides valuable insights for providers and formulary decision makers as it represents the first realworld evaluation of liraglutide's effectiveness to lower A1C, body weight, cholesterol, and blood pressure across BMI groups in clinical practice in the US.
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